J Refract Surg. 2021 Aug;37(8):524-531. doi: 10.3928/1081597X-20210518-01. Epub 2021 Aug 1.
To evaluate visual outcomes, satisfaction, and spectacle independence in non-presbyopic hyperopic patients who underwent bilateral refractive lens exchange with a trifocal intraocular lens (IOL) and to compare them with presbyopic hyperopic patients.
In this retrospective study, patients younger than 40 years underwent bilateral refractive lens exchange with a diffractive trifocal IOL (FineVision Micro F; PhysIOL SA) for hyperopia with at least 3 months of follow-up. A control group of patients older than 50 years was matched by axial length, sex, and follow-up. Safety, efficacy, predictability, patient satisfaction, and spectacle independence were evaluated.
One hundred thirty-three patients (average age = 36.94 ± 2.91 years; range = 21.50 to 40 years) were included in this study. After a mean follow-up of 8.83 ± 5.69 months (range = 2.75 to 77.63 months), the safety and efficacy indexes and predictability within ±1.00 diopters (D) were 1.02%, 0.98%, and 99.62%, respectively, which was not different from the control group ( > .05). No intraoperative complications were recorded. The only postoperative complication was posterior capsule opacification in 21 eyes (7.89%), which was similar to the control group ( > .05). Ninety-seven percent of patients in each group expressed that they were satisfied and all of them in each group reported that they did not use spectacles for distance, intermediate, or near vision.
Refractive lens exchange and trifocal IOL implantation for hyperopia in patients without presbyopia provided the same good visual outcomes as in presbyopic patients with a high rate of patient satisfaction and spectacle independence. .
评估行双眼屈光性晶状体置换术联合三焦点人工晶状体(IOL)治疗非老视性远视患者的术后视力、满意度和脱镜率,并与老视性远视患者进行比较。
本回顾性研究纳入了年龄小于 40 岁且接受过双眼屈光性晶状体置换术联合衍射型三焦点 IOL(FineVision Micro F;PhysIOL SA)治疗的远视患者(至少随访 3 个月)。通过眼轴长度、性别和随访时间匹配了年龄大于 50 岁的对照组患者。评估安全性、有效性、可预测性、患者满意度和脱镜率。
本研究共纳入 133 例患者(平均年龄=36.94±2.91 岁;范围=21.50 至 40 岁)。平均随访 8.83±5.69 个月(范围=2.75 至 77.63 个月)后,安全性和有效性指标以及±1.00 屈光度(D)内的预测性分别为 1.02%、0.98%和 99.62%,与对照组无差异(>0.05)。未记录术中并发症。唯一的术后并发症是 21 只眼(7.89%)发生后发性白内障,与对照组相似(>0.05)。两组各有 97%的患者表示满意,两组各有 100%的患者表示无需戴镜即可满足远、中、近视力需求。
对于无老视的远视患者,行屈光性晶状体置换术联合三焦点 IOL 植入术可获得与老视患者相似的良好视觉效果,患者满意度和脱镜率均较高。